Eikon Therapeutics vs MasterControl
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.
About
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.
MasterControl is the leading QMS and MES platform for regulated life sciences industries, serving 1,100+ companies with $200M revenue in 2025; valued at $1.3B after $150M from Sixth Street, acquired Qualer in Mar 2025.
About
MasterControl is a leading provider of quality management system (QMS) and manufacturing execution system (MES) software for regulated industries, with a primary focus on pharmaceuticals, medical devices, biotechnology, and food and beverage. The company's AI-powered platform digitizes and automates compliance-critical workflows including document control, training management, audit management, change control, corrective and preventive action (CAPA), risk management, and electronic batch records — replacing paper-based processes that are error-prone, audit-vulnerable, and incompatible with modern manufacturing velocity.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.